Protocols
33 protocol(s) meet the specified criteria
Disease Site: Myeloid and Monocytic Leukemia
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
14-1999Biomarker-Based Radiation Dosimetry ProjectOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
AC220-007A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) ConsolidationOpen
BMT-CTN-1101BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic MalignanciesOpen
BMT-CTN-1102A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
BMT-CTN-1202Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTOpen
BMT-CTN-1205BMTCTN 1205: Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical TrialsOpen
CALGB10502Dose Escalation and Phase II Study of Bortezomib (IND #58443, NSC # 681239) Added to Standard Daunorubicin and Cytarabine Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 YearsOpen (affiliates only)
CALGB10503Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 YearsOpen (affiliates only)
CALGB10603A Phase III Randomized, Double-Blind Study Of Induction (Daunorubicin/Cytarabine) And Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (Pkc412) (Ind #101261) Or Placebo In Newly Diagnosed Patients < 60 Years Of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)Open (affiliates only)
CC-5013-AML-002A Phase 2, Multicenter, Single-Arm, Openlabel Study to Evaluate the Activity, Safety and Pharmacokinetics Of Lenalidomide (Revlimid®) In Pediatric Subjects from 1 To &#8804; 18 Years Of Age With Relapsed or Refractory Acute Myeloid Leukemia Open
CLFG316X2202A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associated microangiopathy after hematopoietic precursor cell transplantationOpen
COG-AAML1531Risk-stratified Therapy for Acute Myeloid Leukemia in Down SyndromeOpen
COG-ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
COGAAML08B1Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)Open
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
CP-MGD006-01A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia Open
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1111An Open-Label Dose-Finding Study of Lenalidomide as Consolidation Followed by Lenalidomide Maintenance Therapy for Adults >/= 60 Years of Age with AML in Partial or Complete Response Following Conventional Induction TherapyOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1314A phase II, placebo-controlled, double-blind, randomized trial of pregabalin for the prophylaxis of granulocyte colony stimulating factor (GCSF)-induced bone painOpen
LCCC1404Evaluating the ability of electronic patient symptom reporting to reduce symptom burden during hospitalization for intensive chemotherapyOpen
LCCC1432Longitudinal Assessment of Symptoms, Functional Status, and Quality of Life in Adults with Acute Myeloid LeukemiaOpen (affiliates only)
LCCC1522Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia Open
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1542Leukemia Specific Splice Isoforms as Neo-Antigens for T-cell Immunotherapy Open
LCCC1702Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in Acute Myeloid Leukemia (AML) patients in remission following Allogeneic Stem Cell Transplant or Induction and Consolidation ChemotherapyOpen
LTE1401Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesOpen
NCI9524A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDSOpen
PEVONEDISTAT-2001A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaOpen
TPI-ALV-201A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)Open